Merck’s blockbuster cancer drug Keytruda now costs $210,000 for a year’s treatment in the United States—a staggering figure that has quietly become the new normal for patients battling advanced melanoma, lung cancer and other malignancies under the Trump administration’s pharmaceutical pricing framework. This isn’t just another headline about drug inflation; it’s a symptom of a deeper, systemic failure where lifesaving innovation is held hostage by patent thickets, opaque rebate systems, and confidential deals that shield corporations from accountability while patients face financial ruin.
The $210,000 annual price tag represents a 6% increase from last year, according to a Senate report released this week—but that modest percentage masks a far more troubling trend. Since Keytruda’s launch in 2014, its list price has risen over 400%, far outpacing inflation and even the cost of other biologics. What makes this case particularly egregious is that Keytruda isn’t just any drug; it accounts for nearly half of Merck’s total revenue, making it the cornerstone of the company’s financial empire. Yet despite signing confidential agreements with the Trump administration purportedly to lower drug prices, Merck has instead doubled down on strategies that keep Keytruda’s cost astronomically high—especially in the U.S., where patients pay up to 12 times more than those in Indonesia for the same 200-milligram dose.
This disparity isn’t accidental. It’s the result of a deliberate, multi-layered defense strategy Merck has employed to extend Keytruda’s market exclusivity well beyond the original patent expiration. Through a practice known as “patent evergreening,” the company has filed over 200 additional patents covering everything from dosing regimens to specific biomarker combinations, effectively creating a legal moat that blocks biosimilar competition until at least 2032. As Dr. Ruth Lopert, senior fellow at the Center for Global Development and former senior advisor to the U.S. Food and Drug Administration, explained in a recent interview:
“What we’re seeing with Keytruda isn’t innovation rewarded—it’s innovation weaponized. Every new patent filed isn’t about improving patient outcomes; it’s about delaying generic entry by another six months, another year. The system allows this because we’ve conflated legal exclusivity with therapeutic value, and patients pay the price in both dollars and delayed access.”
The human toll is documented in the Cancer Calculus investigation by the International Consortium of Investigative Journalists (ICIJ), which found that insurers routinely deny coverage for Keytruda based on technicalities, forcing patients into grueling appeals processes while their cancer progresses. One patient in Ohio, featured in the ICIJ series, described selling her home and depleting her retirement savings to afford just eight months of treatment—only to have her insurer retroactively deny coverage because a biomarker test was conducted 11 days outside the approved window. “They deny the medication that is keeping you alive,” she said, her voice trembling. “It’s not healthcare. It’s a financial triage where your life expectancy depends on your zip code and your bank balance.”
These denials aren’t isolated. A 2025 study published in JAMA Oncology found that nearly 30% of initial prior authorization requests for Keytruda were rejected by commercial insurers, with Black and Hispanic patients facing disproportionately higher denial rates—even when clinical guidelines clearly supported treatment. Dr. Elena Rios, president of the National Hispanic Medical Association, testified before the Senate Finance Committee last month:
“We’re not seeing price gouging in a vacuum. We’re seeing it intersect with racial and economic inequities in access. When a drug costs more than the median annual income in many U.S. Households, and then insurers add bureaucratic barriers on top, we’re not practicing medicine—we’re conducting a lottery where survival depends on luck, not necessitate.”
The global contrast is stark. In the United Kingdom, where the National Health Service negotiates prices based on cost-effectiveness thresholds, Keytruda costs approximately $45,000 per year. In Germany, it’s around $55,000. Even in Canada, despite its own struggles with drug pricing, the annual cost averages $65,000—less than a third of the U.S. Price. These differences aren’t due to variations in manufacturing costs or regulatory hurdles; they stem from the absence of value-based pricing mechanisms in the United States, where Medicare is legally prohibited from negotiating drug prices directly—a restriction lobbied for and maintained by the pharmaceutical industry for over two decades.
Merck’s defense, as conveyed through senior vice president Johanna Herrmann to ICIJ, rests on the claim that the confidential Trump administration agreement has a “manageable impact” and is “immaterial across the KEYTRUDA family.” But this characterization ignores the drug’s outsized role in the company’s bottom line. In 2024, Keytruda generated $25 billion in global sales—over 45% of Merck’s total revenue. To call its pricing strategy immaterial is like saying the engine is immaterial to a car’s movement. The truth is that Keytruda’s profitability funds Merck’s entire R&D pipeline, shareholder dividends, and executive compensation packages—creating a perverse incentive to protect its price at all costs, even as patients skip doses, split pills, or abandon treatment altogether.
The broader implications extend beyond oncology. Keytruda’s pricing model has become a blueprint for other pharmaceutical companies seeking to maximize returns on immunotherapies and biologics. As noted in a recent report by the Institute for Clinical and Economic Review (ICER), the U.S. Now spends more per capita on cancer drugs than any other high-income nation, yet achieves no better survival outcomes—suggesting that we are paying premium prices not for superior care, but for monopolistic control.
What’s needed isn’t more voluntary pledges or confidential side deals. It’s structural reform: allowing Medicare to negotiate prices, closing loopholes that enable patent evergreening, and requiring transparency in rebate contracts between pharmacy benefit managers and manufacturers. Until then, stories like this will keep emerging—not as aberrations, but as inevitable outcomes of a system that treats cancer patients not as people in need of care, but as revenue streams to be optimized.
As we confront this reality, the question isn’t whether You can afford to lower drug prices—it’s whether we can afford not to. The next time you hear a pharmaceutical executive defend sky-high costs as the price of innovation, ask them: Innovation for whom? And at what cost to the rest of us?
